Single subcutaneous dose of ADX-038 achieved near-complete alternative pathway suppression for 6 months, supporting potent and selective CFB ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...
Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rare Disease portfolio Omeros is eligible to receive 340 million US dollars in ...
Participants were presented with polyphonic music made of two monophonic streams (PolyOrig condition), with control stimuli where the average pi ...
That’s Hudson, Ohio for you – a town that somehow manages to be both frozen in time and completely alive. Just 30 miles southeast of Cleveland and 15 miles north of Akron, Hudson sits like a perfectly ...
Natchitoches (pronounced “NACK-a-tish”) sits in central Louisiana like a well-kept secret, offering weekend warriors the perfect escape from modern chaos without the tourist-trap prices or pretension.
Novo Nordisk is paying $240 million for global rights to a Phase 3-ready drug from Omeros that could rival immune disorder medications currently available from companies such as AstraZeneca, Novartis, ...
A new study offers hope for brain cancer patients facing memory loss from radiotherapy. By blocking a single immune receptor, scientists preserved cognition in mice without dulling the cancer-killing ...
Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterised by persistent, abnormal eosinophil elevation in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback